Viatris (NASDAQ:VTRS) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Viatris to reach your target.
Based on historical returns, we believe that Viatris can grow its free cash at a rate of about 3%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| VTRS Price (Viatris stock price per share) |
$19.63 | |
|
|
VTRS Fair Price (based on intrinsic value) |
$20.02 |
| VTRS Safety Price (based on a variable margin of safety) | $12.01 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 26% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 0% lower than other Drug Manufacturers - General stocks | |
| Free Cash Flow Jitter | 26% | |
| Dividend Yield | 2.41% (tax impact) | Shares Shorted | 35,240,834 |
No open-market insider buys or sells are recorded for the last 12 months.
Open-market buys and sells reported by Viatris's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2024-11-11 | Campbell Paul (See Remarks) | Sell | 26,925 | $12.88 |
| 2024-09-12 | Malik Rajiv | Sell | 139,681 | $11.66 |
| 2024-09-12 | Malik Rajiv | Sell | 60,319 | $11.71 |
| 2024-08-30 | Malik Rajiv | Sell | 50,000 | $12.00 |
| 2024-08-28 | Malik Rajiv | Sell | 50,000 | $11.90 |
| 2024-08-23 | Malik Rajiv | Sell | 100,000 | $11.75 |
| 2024-08-22 | Malik Rajiv | Sell | 100,000 | $11.73 |
| 2024-08-21 | Malik Rajiv | Sell | 100,000 | $11.75 |
| 2024-06-14 | Malik Rajiv | Sell | 264,300 | $10.18 |
| 2024-06-13 | Malik Rajiv | Sell | 85,660 | $10.52 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 35,240,834 shares shorted. With 1,139,461,355 shares available for purchase and an average trading volume over the past 10 trading days of 11,660,120, it would take at least 3.0 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2018 | 1792044 | 2,090 |
| 2019 | 1792044 | 1,571 |
| 2020 | 1792044 | 996 |
| 2021 | 1792044 | 2,726 |
| 2022 | 1792044 | 2,685 |
| 2023 | 1792044 | 2,561 |
| 2024 | 1792044 | 1,941 |
| 2025 | 1792044 | 1,927 |
Download the yearly data as CSV.
How to read this: why companies buy back shares, dividend yield explained.
Over the 4 fiscal years from 2018 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $8,518 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
Trendshare has no dividend payment facts for these years, so the table shows no dividends. That is a gap in the data, not a finding about the company.
In 4 of the 4 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $1,433 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2025, cash spent repurchasing shares was $501 million, 26.0% of estimated free cash flow of $1,927 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2018 | 2,090 | n/a | 432 | 432 | 20.7% |
| 2023 | 2,561 | n/a | 250 | 250 | 9.8% |
| 2024 | 1,941 | n/a | 250 | 250 | 12.9% |
| 2025 | 1,927 | n/a | 501 | 501 | 26.0% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $11,434 million in 2018 and $14,300 million in 2025, a compound annual growth rate of 3.2% over 7 years.
Revenue fell 3.0% from 2024 to 2025.
Our estimated free cash flow was $1,927 million in 2025, 13.5% of revenue. In 2018 the estimated margin was 18.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2018 | 11,434 | 2,090 | 18.3% |
| 2019 | 11,501 | 1,571 | 13.7% |
| 2020 | 11,946 | 996 | 8.3% |
| 2021 | 17,886 | 2,726 | 15.2% |
| 2022 | 16,263 | 2,685 | 16.5% |
| 2023 | 15,427 | 2,561 | 16.6% |
| 2024 | 14,739 | 1,941 | 13.2% |
| 2025 | 14,300 | 1,927 | 13.5% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $1,322 million against total liabilities of $22,482 million, or 5.9% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 60.4% of total assets in 2025, compared with 62.0% in 2019, a decrease of 1.5 percentage points.
Stockholders equity was $14,711 million in 2025, compared with $11,884 million in 2019, a rise of 23.8%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 6.7% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2019 | 31,256 | 476 | 19,372 | 11,884 |
| 2020 | 61,553 | 844 | 38,599 | 22,954 |
| 2021 | 54,843 | 701 | 34,350 | 20,493 |
| 2022 | 50,022 | 1,260 | 28,950 | 21,072 |
| 2023 | 47,686 | 992 | 27,218 | 20,467 |
| 2024 | 41,501 | 735 | 22,865 | 18,636 |
| 2025 | 37,193 | 1,322 | 22,482 | 14,711 |
Free cash flow was positive in all 8 fiscal years we have for Viatris under its current SEC filer.
The latest three years average $2,143 million in free cash flow against $1,552 million for the earliest three, which is a sharp rise.
Free cash flow is uneven from year to year, with a variability measure of 26%.
The price of $19.63 falls between the safe value ($12.01) and fair value ($20.02) for Viatris.
Viatris pays a dividend yield of 2.41%.
Our value investing guide explains how to test these numbers against the filings themselves.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 26% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is in line with the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Viatris, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Viatris (VTRS) | 22,505 | - | 2.4% | - | 2% below |
| United Therapeutics Corporation (UTHR) | 23,625 | 20.9 | - | 1.5% | 30% above |
| Jazz Pharmaceuticals plc (JAZZ) | 14,780 | 68.1 | - | 3.4% | 53% below |
| Zoetis (ZTS) | 32,144 | 13.5 | 2.6% | - | 865% above |
| Elanco Animal Health Incorporated (ELAN) | 12,866 | - | - | - | 96% above |
| Alkermes plc (ALKS) | 7,552 | - | - | 1.5% | 315% above |
| Corcept Therapeutics Incorporated (CORT) | 7,112 | 48.9 | - | 0.0% | 858% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1792044.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: VTRS annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Viatris have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to VTRS: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market